Not yet recruiting
Retinal dystrophy
Not yet recruitingA Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function
InvestigationalNo placebo
A Study of ATSN-201 Gene Therapy for Patients with X-linked Retinoschisis (RS1-associated) to Assess Safety and Visual Function
InvestigationalNo placebo
- Disease:Retinal dystrophy
- Substances:Ziloretgene parvec
Countries:
France
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Ziloretgene parvec



